US/UK/Canada

Share

Contacts

  • Malene Brondberg

    VP, Investor Relations and Corporate Communications


    Paternoster House, 65 St. Paul’s Churchyard, London EC4M 8AB, UK
    +47 22 18 33 01
    +44 7561 431 762
    +47 22 58 00 07
    http://www.nordicnanovector.com
    • Pick a time period -

    Nordic Nanovector ASA: Share capital increase registered

    Oslo, Norway, 17 June 2019. Reference is made to the stock exchange notice published by Nordic Nanovector ASA (the "Company") (OSE: NANO) on 31 May 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of RSUs. In addition, two participants in the Company's previous share option program, not being primary insiders, have exercised a total number of 407,253 options through exercise of a corresponding number of free-standing warrants. 392,255 of the options are exercised at a strike

    Nordic Nanovector Presentations at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting

    Oslo, Norway, 11 June 2019 Nordic Nanovector ASA (OSE: NANO) announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® (177Lu-lilotomab satetraxetan) and with 212Pb-NNV003, a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) coupled with the alpha-particle-generator lead-212 (212Pb), at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting, to be held in Anaheim, CA, USA on 22-24 June. Details of the presentations are: Combination of

    Nordic Nanovector to present preclinical studies with 212Pb-NNV003, a novel CD37-specific Targeted Alpha Therapy for CLL and NHL, at TRP 2019

    Oslo, Norway, 6 June 2019 Nordic Nanovector ASA (OSE: NANO) announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with 212PB-NNV003, a novel Targeted Alpha Therapy comprising its proprietary CD37-specific antibody (NNV003) coupled with the alpha-particle generating radioisotope lead-212 (212Pb) in models of chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) at the Targeted Radiopharmaceuticals Summit taking place in Munich, Germany on 12-13 June. The presentation will take place at 13th June 09:30-10:00 CEST and is

    Nordic Nanovector: European patent granted for Betalutin® or Humalutin® in combination with anti-CD20 antibodies for treating NHL

    Oslo, Norway 3 June 2019 Nordic Nanovector ASA (OSE: NANO) announces that the European Patent Organisation (EPO) has granted the company’s European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin’s lymphoma (NHL). The same patent has also been issued in Japan, China, Australia, Hong Kong, Israel, Russia and Singapore while the patent is pending in USA, Brazil, Canada, Indonesia, India, Korea, Mexico, New Zealand, Philippines, Ukraine and South Africa. This patent is a result of Nordic Nanovector’s continued

    Nordic Nanovector ASA: Increase of share capital

    Three of the board members of Nordic Nanovector ASA (the "Company"), Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a total number of 11,840 RSUs that were issued to them in June 2018 after they had elected to receive all or part of their remuneration for the period from the annual general meeting in 2018 to the annual general meeting in 2019 in RSUs. In addition, a former board member has resolved to settle a total number of 7,000 RSUs that the Company has previously issued as remuneration under the RSU-program. Each RSU gives the right to subscribe for one

    Nordic Nanovector to present at Redeye Pre-ASCO seminar, Jefferies Healthcare conference and ABGSC Oncology seminar

    Oslo, Norway, 27 May 2019 Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming investor conferences during May and June: ·  Redeye Pre-ASCO seminar in Stockholm on 28 May ·  Jefferies Healthcare conference in New York on 4-7 June ·  ABGSC Oncology seminar in Oslo on 11 June The company presentation to be given at these events will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentations on the first day of each conference. For further

    Nordic Nanovector ASA - Allocation of PSUs

    The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 23 May 2019 resolved to grant 10,000 Performance Share Units ("PSUs") to a new employee under the Company's equity incentive plan that was approved at the Company's annual general meeting held on 25 April 2019 (the "AGM"). In accordance with the resolution at the AGM the PSUs are secured by a corresponding number of free-standing warrants. The sole purpose of the free-standing warrants is to ensure delivery of shares in the Company upon exercise of the PSUs. The free-standing warrants do not give

    Nordic Nanovector ASA: Resultat for første kvartal 2019

    Oslo, 23. mai 2019 Nordic Nanovector ASA (OSE: NANO) publiserer i dag sine resultater for første kvartal 2019. Selskapets ledelse vil gi en presentasjon av resultatene klokken 08:30 på Thon Hotel Vika Atrium i Oslo. Se ytterligere informasjon nedenfor. - Parallelt med fremgangen i de kliniske utviklingsprogrammene med Betalutin®, inkludert PARADIGME-studien, setter vi også i gang andre nødvendige forberedelser til kommersialisering. Aktiviteter som produksjonsforberedelser er avgjørende for å sikre en at søknadsprosessen for myndighetsgodkjenning skjer effektivt og på riktig tidspunkt.

    Nordic Nanovector ASA – Results for the First Quarter 2019

    Oslo, Norway, 23 May 2019 Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2019. A presentation by the company’s senior management team will take place today in Oslo at 08:30 CEST, see details below. Eduardo Bravo, CEO, commented: “As we advance the clinical development programmes with Betalutin®, including PARADIGME, we are also beginning to initiate some of the other pre-commercialisation activities, such as manufacturing, that are crucial to ensure that we can submit our regulatory filing in a timely and efficient manner. The recent fundraising is

    Nordic Nanovector: Archer-1 phase 1b Betalutin®/rituximab combination trial advances to next cohort

    Oslo, Norway, 21 May 2019 Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL), the Betalutin® dose has been escalated to 15 MBq/kg for the next cohort of patients. Archer-1 is a Phase 1b open-label, single-arm, multi-centre dose-escalation trial to assess the safety and preliminary activity of combining CD37-targeted Betalutin® with CD20-targeted RTX in 20-25

    Nordic Nanovector ASA: Invitation to First Quarter 2019 Results Presentation and Webcast

    Oslo, Norway, 16 May 2019 Nordic Nanovector ASA (OSE: NANO) announces that it will report its first quarter 2019 results on Thursday, 23 May 2019. A presentation by Nordic Nanovector’s senior management team will take place at 8:30am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: NYLAND  The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports

    Nordic Nanovector ASA: Allocation of restricted stock unites (RSUs) to the board of directors

    Oslo, Norway, 10 May 2019 Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANO) annual general meeting held on 25 April 2019 in Oslo, Norway (the "AGM"). At the AGM, the shareholders approved the issuance of restricted stock units ("RSUs") to board members who elect to receive all or parts of their remuneration, for the period from the annual general meeting in 2019 to the annual general meeting in 2020, in the form of RSUs.   The RSUs are non-transferable and each RSU give the right and obligation to acquire one share in the Company at a price

    Nordic Nanovector appoints Fredrik Haavind as Head of Legal and Compliance

    Oslo, Norway, 29 April 2019 Nordic Nanovector ASA (OSE: NANO) announces the appointment of Fredrik Haavind as the newly established Head of Legal and Compliance. Mr Haavind has 16 years of broad legal and compliance experience in Norwegian and International businesses, including international contracts law, governance and compliance, M&A, corporate and securities laws and regulations, with experience from in-house legal departments, law firms and the courts. He joins Nordic Nanovector from Fugro N.V., a global provider of geo-intelligence listed on Euronext, Amsterdam, where he acted as

    Nordic Nanovector ASA: Annual General Meeting held

    Oslo, Norway, 25 April 2019 The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 25 April 2019 in Oslo, Norway. All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 4 April 2019. The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact: Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@

    Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

    Oslo, Norway, 10 April 2019 Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation (SCT) has now reviewed safety data from the first three cohorts of patients. Based on the data, the SRC approved advancing the trial to the next and final cohort with the dose regimen 20 MBq/kg Betalutin and a lilotomab pre-dose of 100 mg/m2. The

    Nordic Nanovector ASA: Notice of Annual General Meeting on 25 April 2019

    Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 25 April 2019 at 15.00 hours CEST at Thon Hotel Vika Atrium, Munkedamsveien 45 in Oslo. The full notice with appendices and the recommendation from the Nomination Committee are attached. The notice and the documents to which it refers are also available on www.nordicnanovector.com. Shareholders wishing to attend the Annual General Meeting, in person or by proxy, must complete and return the attendance form or power of attorney form attached to the notice to Nordea Bank Abp, Issuer Service, Postboks

    Nordic Nanovector ASA publishes 2018 Annual Report

    Oslo, Norway, 3 April 2019 Nordic Nanovector ASA has today published its 2018 Annual Report, including the complete 2018 Annual Accounts with notes. This report is attached to this announcement and available on Nordic Nanovector ASA’s website: www.nordicnanovector.com. For further information, please contact:  IR enquiries   Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com International Media Enquiries   Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email:

    Nordic Nanovector: Promising results from preclinical studies with a novel CD37-targeted alpha therapy for B-cell tumours presented at TAT11

    Oslo, Norway, 2 April 2019 Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported today in an oral presentation at TAT11, the 11th International Symposium on Targeted-Alpha-Therapy (1-4 April, Ottawa, Canada). The research collaboration with Orano Med (formerly known as AREVA Med) was established in June 2016 to develop and investigate a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) and

    Nordic Nanovector to present at DNB's SME conference and Kempen Life Science conference

    Oslo, Norway, 28 March 2019 Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming investor conferences during April: ·  DNB's 15th Annual Small & Medium Enterprises (SME) Conference in Oslo on 4 April ·  The 12th Kempen Life Sciences Conference in Amsterdam on 16-17 April The company presentation will be available on the investors and media page on the first day of the conference. For further information, please contact:  IR enquiries Malene Brondberg, VP Investor Relations and

    Nordic Nanovector ASA: Increased share capital following exercise of employee share options

    Oslo, Norway, 18 March 2019. An individual participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO) previous share option program, not being a primary insider, has exercised a total number of 17,392 options through exercise of a corresponding number of free-standing warrants. 14,374 of the options are exercised at a strike price of NOK 30.00 per share, and 3,018 of the options are exercised at a strike price of NOK 14.24. Each free-standing warrant gives the right to receive one share in the Company. Following exercise of the 17,392 free-standing warrants, the Company's

    Nordic Nanovector ASA – Share capital increase registered

    Oslo, Norway, 14 March 2019 Reference is made to the stock exchange notice on 6 March 2019 where Nordic Nanovector ASA (the "Company") announced the final result of the repair offering, in which 69,051 shares, each with a nominal value of NOK 0.20, at a subscription price of NOK 45.00 (the "Offer Shares") were allocated.  The share capital increase pertaining to the Offer Shares has been registered in the Norwegian Register of Business Enterprises. Following the share capital increase of NOK 13,810.20, the share capital of the Company is NOK 10,934,042.20 divided on 54,670,211 shares,

    Financial calendar for Nordic Nanovector ASA

    FINANCIAL YEAR 2018 03.04.2019 - Annual Report FINANCIAL YEAR 2019 22.08.2019 - Half-yearly Report 25.04.2019 - Annual General Meeting 23.05.2019 - Quarterly Report - Q1 19.11.2019 - Quarterly Report - Q3 This information is published pursuant to the requirements set out in the Continuing obligations. For further information, please contact:  IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com About Nordic Nanovector:  Nordic Nanovector is committed to develop and

    Nordic Nanovector to attend Cowen Health Care Conference, BioCapital Europe and Stifel Nordic Healthcare Seminar

    Oslo, Norway, 11 March 2019 Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming investor conferences during March: ·  Cowen 39th Annual Health Care Conference in Boston, USA on 11-13 March ·  BioCapital Europe in Amsterdam, the Netherlands on 14 March ·  Stifel Conference - Nordic Healthcare Seminar in London, UK on 27 March The company presentation will be available on the investors and media page on the first day of the conference. For further information, please contact:  IR

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe